PCN81 Cost-Effectiveness Analysis of Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous CELL Carcinoma in Patients Whose Tumor Expressed Programmed Death-Ligand 1 at Combined Positive Score ≥1 in France
2020
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI